Author: Editor
ViiV Healthcare announces FDA priority review designation for dolutegravir as a potential treatment for HIV infection
Issued: London, UK ViiV Healthcare today announced that the U.S. Food and Drug Administration (FDA) has granted a priority review…
FY 2012: Good performance across the board, Nestlé model delivered again
Follow today’s events live08:00 CET Investor webcast10:00 CET Press conference webcastFull details in Events Sales of CHF 92.2 billion,…
150th anniversary in 2016 – Nestlé to create visitors centre in Henri Nestlé’s historic buildings in Vevey
To mark its 150th anniversary in 2016, Nestlé has decided to transform the buildings formerly belonging to Henri Nestlé into…
Regulatory update – GSK announces European submission for MEK monotherapy and BRAF/MEK combination therapy in metastatic melanoma
Issued: Thursday 7 February 2013, London UK – LSE Announcement GlaxoSmithKline (GSK) plc today announced submission of a Marketing Authorisation…
Results announcement for the fourth quarter 2012
Issued: London, UK – LSE announcement GSK delivers 2012 core EPS of 112.7p and returns £6.3 billion to shareholders Group…
Governor Appoints Interim Leadership of Two Cabinet Agencies
Governor Appoints Interim Leadership of Two Cabinet Agencies – State of Delaware News Read the latest news on coronavirus in…
GSK announces support for AllTrials campaign for clinical data transparency
Issued: London UK GSK today further demonstrated its commitment to clinical trial transparency by announcing its support for the AllTrials…
GSK increases stake in its publicly-listed Consumer Healthcare subsidiary in India to 72.5 per cent
Issued: London UK – LSE Announcement GlaxoSmithKline plc (LSE: GSK) announced today that, pursuant to the voluntary open offer undertaken…
GlaxoSmithKline starts Phase III study to test combined BRAF/MEK inhibition in patients with BRAF positive melanoma following surgery
Issued: London UK GlaxoSmithKline plc. today announced the start of COMBI-AD, a Phase III study evaluating the combination of dabrafenib,…
GSK response to news article in The Guardian on UK legal proceedings related to Avandia (rosiglitazone)
30 January 2013 Responding to a news article in The Guardian this morning on UK legal proceedings related to our type…
GSK and Biological E. announce joint venture to develop combination vaccine for India and other developing countries
Issued: Monday 28 January 2013, London UK and Mumbai/Hyderabad, India GlaxoSmithKline (GSK) and Biological E Limited (Biological E.), a leading…
GSK appoints Hans Wijers to its Board as a Non-Executive Director
Issued: Thursday 24 January 2013, London UK – LSE Announcement GlaxoSmithKline plc (LSE: GSK) today announced the appointment of Hans…
GSK signs up to UK Government’s Public Health Responsibility Deal
Tuesday 22 January 2013, London UK As a global healthcare company, at GSK we believe we have a responsibility to…
Regulatory update – GSK announces submission of albiglutide BLA to the US FDA for the treatment of type 2 diabetes
Issued: Monday 14 January 2013, London UK – LSE Announcement GlaxoSmithKline (GSK) plc today announced a regulatory submission to the…
Markell Announces Three Judicial Nominations
Markell Announces Three Judicial Nominations – State of Delaware News Read the latest news on coronavirus in Delaware. More Info…